The Losartan Market is estimated at US$1.9 billion in 2026 and is projected to grow at a CAGR of 4.2% to reach US$2.6 billion by 2034.
Relevant uses and settings include blood pressure control, cardiovascular risk management, renal support pathways, hospital formularies, retail pharmacy, and chronic care treatment programs. Commercial considerations include price pressure, supply disruptions, generic competition, and competition from other antihypertensive therapies and combination treatment approaches.
This product will be delivered within 1-3 business days.
Market Overview
The Losartan Market covers pharmaceutical products containing losartan used in hypertension management and broader cardiovascular care across retail, hospital, and chronic therapy settings.Relevant uses and settings include blood pressure control, cardiovascular risk management, renal support pathways, hospital formularies, retail pharmacy, and chronic care treatment programs. Commercial considerations include price pressure, supply disruptions, generic competition, and competition from other antihypertensive therapies and combination treatment approaches.
Key Companies Analysed
- Merck & Co.
- Teva Pharmaceutical
- Viatris
- Aurobindo Pharma
- Sun Pharma
- Dr. Reddy's Laboratories
- Torrent Pharmaceuticals
- Zydus Lifesciences
- Lupin
- Cipla
- Sandoz
- Apotex
- Hikma Pharmaceuticals
- Amneal Pharmaceuticals
- Glenmark
- Alembic Pharmaceuticals
- Aurobindo Pharma USA
- Intas Pharmaceuticals
- Pfizer
- Sanofi
Geographic Coverage
- North America - Market data and outlook to 2034
- United States
- Canada
- Mexico
- Europe - Market data and outlook to 2034
- Germany
- United Kingdom
- France
- Italy
- Spain
- Netherlands
- Switzerland
- Poland
- Sweden
- Russia
- Asia-Pacific - Market data and outlook to 2034
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Malaysia
- Vietnam
- Middle East and Africa - Market data and outlook to 2034
- Saudi Arabia
- South Africa
- Iran
- UAE
- Egypt
- South and Central America - Market data and outlook to 2034
- Brazil
- Argentina
- Chile
- Peru
Report Delivery and Support
- Updated PDF report and an MS Excel workbook containing market tables and figures.
- 7-day post-sale analyst support for clarifications and in-scope supplementary data.
- Complimentary report update covering the latest available data and relevant market developments.
This product will be delivered within 1-3 business days.
Table of Contents
1. Contents and Report Guide
2. Global Losartan Market Overview
3. Losartan Market Dynamics
4. Losartan Market Strategic Analysis
5. Global Losartan Market Size, Share and Forecast, 2025-2034
6. North America Losartan Market Outlook to 2034
7. Europe Losartan Market Outlook to 2034
8. Asia-Pacific Losartan Market Outlook to 2034
9. Middle East and Africa Losartan Market Outlook to 2034
10. South and Central America Losartan Market Outlook to 2034
11. Losartan Market Competitive Landscape
12. Appendix
Companies Mentioned
- Merck & Co.
- Teva Pharmaceutical
- Viatris
- Aurobindo Pharma
- Sun Pharma
- Dr. Reddy's Laboratories
- Torrent Pharmaceuticals
- Zydus Lifesciences
- Lupin
- Cipla
- Sandoz
- Apotex
- Hikma Pharmaceuticals
- Amneal Pharmaceuticals
- Glenmark
- Alembic Pharmaceuticals
- Aurobindo Pharma USA
- Intas Pharmaceuticals
- Pfizer
- Sanofi
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | October 2026 |
| Forecast Period | 2026 - 2034 |
| Estimated Market Value in 2026 | 1.9 Billion |
| Forecasted Market Value by 2034 | 2.6 Billion |
| Compound Annual Growth Rate | 4.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
